Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764614 | 1.00 | FUCA1 (0.56) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL1574151 | 1.00 | FUCA1 (0.56) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL4089384 | 0.89 | FUCA1 (0.50) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL16759827 | 0.87 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL16775256 | 0.87 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL24893928 | 0.85 | FUCA1 (0.46) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL19327458 | 0.83 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL5836807 | 0.83 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL7575241 | 0.83 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 | |
| SCHEMBL1088536 | 0.83 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| EP-2177511-A2 | Process for preparing 3,6-disubstituted azabicyclo derivatives | Ranbaxy Laboratories Limited (IN) | 2010-04-21 | — | — | EP | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| US-20080319002-A1 | Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
| EP-1572648-B1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-07-09 | — | — | EP | disclosed |
| US-7342011-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342011-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2008010238-A2 | ANTIDIABETIC AZABICYCLO [3. 1. 0] HEXAN COMPOUNDS | LUPIN LIMITED (IN) | 2008-01-24 | — | — | WO | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7232835-B2 | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-19 | — | — | US | disclosed |
| US-20060217432-A1 | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | US | disclosed |
| EP-1572648-A1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052857-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217432-A1 | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | FUCA1 2791/4885SIGMAR1 605/4885S1PR1 184/4885 |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | FUCA1 143/4885SIGMAR1 2370/4885S1PR1 4112/4885 |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | FUCA1 2362/4885SIGMAR1 476/4885S1PR1 181/4885 |
| US-20080319002-A1 | Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | FUCA1 1472/4885SIGMAR1 352/4885S1PR1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.